Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice

Byungha Chung, Sung Joon Hong, Moo Sang Lee

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH. Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment. Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45-64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth. Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed.

Original languageEnglish
Pages (from-to)159-165
Number of pages7
JournalInternational Journal of Urology
Volume12
Issue number2
DOIs
Publication statusPublished - 2005 Feb 1

Fingerprint

Doxazosin
Prostatic Hyperplasia
General Practice
Prostate
Nonparametric Statistics
Blood Pressure
Therapeutics
Safety
Asthenia
Dyspepsia
Dizziness
Adrenergic Receptors
Population
Multicenter Studies
Mouth
Placebos

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{ddc37cf1c6ef4dea9728903f6a5a00e7,
title = "Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice",
abstract = "Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH. Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment. Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48{\%}; similarly, the obstructive and irritative subscores were reduced from baseline by 51{\%} and 39{\%}, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45-64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth. Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed.",
author = "Byungha Chung and Hong, {Sung Joon} and Lee, {Moo Sang}",
year = "2005",
month = "2",
day = "1",
doi = "10.1111/j.1442-2042.2005.00998.x",
language = "English",
volume = "12",
pages = "159--165",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "2",

}

Doxazosin for benign prostatic hyperplasia : An open-label, baseline-controlled study in Korean general practice. / Chung, Byungha; Hong, Sung Joon; Lee, Moo Sang.

In: International Journal of Urology, Vol. 12, No. 2, 01.02.2005, p. 159-165.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Doxazosin for benign prostatic hyperplasia

T2 - An open-label, baseline-controlled study in Korean general practice

AU - Chung, Byungha

AU - Hong, Sung Joon

AU - Lee, Moo Sang

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH. Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment. Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45-64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth. Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed.

AB - Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH. Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment. Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45-64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth. Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed.

UR - http://www.scopus.com/inward/record.url?scp=16244389702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16244389702&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2005.00998.x

DO - 10.1111/j.1442-2042.2005.00998.x

M3 - Article

C2 - 15733110

AN - SCOPUS:16244389702

VL - 12

SP - 159

EP - 165

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 2

ER -